Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT06881251 · Janssen Research & Development, LLC · PHASE2 · terminated · last registry update 2026-07-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated: futility criteria met at interim efficacy analysis.” | – | Registry record, Janssen Research & Development, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL4R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Phase 3 first posted: Sanofi, Dupilumab coformulated with berahyaluronidase alfa + Dupilumab (NCT07919899)
- 2026-11-03Also stopped (terminated): Johns Hopkins University, Dupilumab - Discontinuation + Dupilumab - Dose Reduction (NCT06116526)
- 2026-10-27Also stopped (terminated): Innovent Biologics (Suzhou) Co. Ltd., Dupilumab + Placebo (NCT07330934)
- 2026-09-21Also stopped (terminated): University Hospital, Toulouse, Dupilumab Prefilled Syringe (NCT04244006)
- 2026-09-18Results posted on the registry: Beth Israel Deaconess Medical Center, Dupilumab (NCT05128383)
- 2026-08-24Phase 3 first posted: Pfizer, Tilrekimig + Dupilumab (NCT07783425)
- 2026-08-10Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., Dupilumab Injection + IBI3027 (NCT07754786)
- 2026-08-05Results posted on the registry: Medical University of South Carolina, Dupilumab (NCT05964465)
- 2026-06-04Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Dupilumab + Vanicream- Dupilumab-naïve (NCT05436535)
- 2026-05-29Results posted on the registry: Stanford University, Omalizumab + Dupilumab (NCT03679676)
- 2026-05-22Also stopped (terminated): Psoriasis Treatment Center of Central New Jersey, tralokinumab (NCT06773455)
- 2026-04-27Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Dupixent® + Grazax® (NCT04502966)
- 2026-03-06Results posted on the registry: Regeneron Pharmaceuticals, dupilumab + Matching Placebo (NCT04206553)
- 2026-02-27Results posted on the registry: Brigham and Women's Hospital, Dupilumab (NCT03935971)
- 2026-02-04Phase 3 first posted: Jiangsu Genscend Biopharmaceutical Co., Ltd, GS101 injection + DUPIXENT® (NCT07386743)
- 2026-01-07Results posted on the registry: Andrew J Long, PharmD, Dupilumab (NCT04148352)
- 2026-01-07Also stopped (terminated): Andrew J Long, PharmD, Dupilumab (NCT04148352)
- 2026-01-02Results posted on the registry: Regeneron Pharmaceuticals, dupilumab (NCT05590585)
- 2025-12-30Phase 3 first posted: Université de Sherbrooke, Dupilumab Prefilled Syringe + Placebo Injection (NCT07309614)
- 2025-12-22Results posted on the registry: Sanofi, Dupilumab SAR231893 + Placebo (NCT04684524)
- 2025-11-28Also stopped (withdrawn): Regeneron Pharmaceuticals, dupilumab (NCT07187089)
- 2025-11-21Results posted on the registry: Mayo Clinic, Dupilumab 300Mg Solution for Injection (NCT04256759)
- 2025-11-21Results posted on the registry: Sanofi, Dupilumab (SAR231893/REGN668) + Asthma controller therapies (incl. prednisone/prednisolone) (NCT03560466)
- 2025-11-19Results posted on the registry: Sanofi, Dupilumab (NCT05526521)
- 2025-11-14Results posted on the registry: University of California, San Francisco, Dupilumab (NCT03293030)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision